MX2019012158A - Tratamiento para el asma con anticuerpo anti-tslp. - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp.

Info

Publication number
MX2019012158A
MX2019012158A MX2019012158A MX2019012158A MX2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A
Authority
MX
Mexico
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
MX2019012158A
Other languages
English (en)
Spanish (es)
Inventor
R Parnes Jane
Griffiths Janet
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019012158A publication Critical patent/MX2019012158A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019012158A 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp. MX2019012158A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
MX2019012158A true MX2019012158A (es) 2019-12-16

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012158A MX2019012158A (es) 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp.

Country Status (21)

Country Link
US (3) US10828365B2 (OSRAM)
EP (1) EP3609917A1 (OSRAM)
JP (4) JP7330896B2 (OSRAM)
KR (2) KR102666879B1 (OSRAM)
CN (1) CN110573525A (OSRAM)
AU (2) AU2018253118B2 (OSRAM)
BR (1) BR112019021482A2 (OSRAM)
CA (1) CA3059364A1 (OSRAM)
CL (1) CL2019002897A1 (OSRAM)
CO (1) CO2019011462A2 (OSRAM)
IL (1) IL269791B (OSRAM)
JO (1) JOP20190243A1 (OSRAM)
MX (1) MX2019012158A (OSRAM)
MY (1) MY207509A (OSRAM)
PE (1) PE20200484A1 (OSRAM)
PH (1) PH12019502331A1 (OSRAM)
SG (1) SG11201909322VA (OSRAM)
TN (1) TN2019000289A1 (OSRAM)
TW (2) TWI856945B (OSRAM)
UY (1) UY37676A (OSRAM)
WO (1) WO2018191479A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24533B1 (es) * 2015-09-09 2021-07-02 Novartis Ag Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN116751295A (zh) 2019-06-04 2023-09-15 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
WO2021007533A1 (en) 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof
HUE071069T2 (hu) * 2019-10-28 2025-07-28 Medimmune Ltd Tímusz sztrómális limfopoietint (TSLP) kötõ antitestek szárazpor készítményei és eljárások ezek alkalmazására
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技(成都)有限公司 一种tslp相关病症治疗剂的开发和应用
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-TSLP ANTIBODIES AND USES THEREOF
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
JP2023513312A (ja) * 2020-02-13 2023-03-30 アムジェン インコーポレイテッド ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法
PE20230115A1 (es) * 2020-02-18 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
EP4302778A4 (en) * 2021-03-03 2025-03-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-TSLP ANTIBODY
TW202306982A (zh) * 2021-04-19 2023-02-16 英商梅迪繆思有限公司 具有改善的穩定性的抗tslp fab
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
AU2022262421A1 (en) 2021-04-23 2023-10-19 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR130862A1 (es) 2022-10-26 2025-01-29 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR133648A1 (es) * 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos anti-tslp y sus usos
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
AU2010315304B2 (en) 2009-11-04 2014-03-27 Merck Sharp & Dohme Llc Engineered anti-TSLP antibody
WO2012007495A1 (en) * 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2015061441A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
UY36578A (es) * 2015-03-11 2016-09-30 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Also Published As

Publication number Publication date
BR112019021482A2 (pt) 2020-05-12
CL2019002897A1 (es) 2020-03-06
KR20240070727A (ko) 2024-05-21
US20210052726A1 (en) 2021-02-25
CN110573525A (zh) 2019-12-13
AU2018253118B2 (en) 2025-04-10
JOP20190243A1 (ar) 2019-10-13
UY37676A (es) 2018-10-31
JP2025170430A (ja) 2025-11-18
JP2023099233A (ja) 2023-07-11
PH12019502331A1 (en) 2020-09-28
EP3609917A1 (en) 2020-02-19
MY207509A (en) 2025-02-28
CO2019011462A2 (es) 2019-10-31
TW201838652A (zh) 2018-11-01
TWI856945B (zh) 2024-10-01
TW202523688A (zh) 2025-06-16
KR102666879B1 (ko) 2024-05-23
PE20200484A1 (es) 2020-03-03
JP2020516647A (ja) 2020-06-11
KR20190140956A (ko) 2019-12-20
AU2025204735A1 (en) 2025-07-17
AU2018253118A1 (en) 2019-10-24
US10828365B2 (en) 2020-11-10
TN2019000289A1 (en) 2021-05-07
US20250032608A1 (en) 2025-01-30
JP7330896B2 (ja) 2023-08-22
SG11201909322VA (en) 2019-11-28
CA3059364A1 (en) 2018-10-18
WO2018191479A1 (en) 2018-10-18
IL269791A (en) 2019-11-28
JP2024150751A (ja) 2024-10-23
IL269791B (en) 2022-07-01
US20180296669A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MY210545A (en) Chimeric receptors to flt3 and methods of use thereof
PH12018500482A1 (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MY205760A (en) Humanized antibodies against c-kit
MY195110A (en) Antibodies to PD-1 and uses Thereof
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MY186352A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
ZA202205936B (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
MY201744A (en) Binding polypeptides and methods of making the same
MX2025008918A (es) Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp
MX2010007355A (es) Extracto de heteropterys brachiata, metodo de obtencion y uso para el tratamiento de ansiedad y depresion.